Recent Quotes (30 days)

You have no recent quotes
chg | %

Oncolytics Biotech, Inc. (USA)  

(Public, OTCMKTS:ONCYF)   Watch this stock  
Find more results for NASDAQ:ONCY
+0.002 (0.34%)
Apr 25 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.67 - 0.73
52 week 0.14 - 0.85
Open 0.72
Vol / Avg. 155,159.00/271,027.00
Mkt cap 86.53M
P/E     -
Div/yield     -
EPS -0.09
Shares 121.26M
Beta 1.14
Inst. own 1%
May 4, 2017
Q1 2017 Oncolytics Biotech Inc Earnings Release (Estimated) Add to calendar
May 2, 2017
Oncolytics Biotech Inc at Bloom Burton & Co. Healthcare Investor Conference - 1:30PM EDT - Add to calendar
Mar 10, 2017
Q4 2016 Oncolytics Biotech Inc Earnings Release

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -125.90% -71.85%
Return on average equity -158.81% -85.62%
Employees 21 -
CDP Score - -


210-1167 Kensington Cres NW
+1-403-6707377 (Phone)
+1-403-2830858 (Fax)

Website links


Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Officers and directors

Wayne F. Pisano Chairman of the Board
Matthew C. Coffey Ph.D. President, Chief Executive Officer, Chief Operating Officer, Director
Kirk J. Look Chief Financial Officer
George M. Gill M.D. Senior Vice President - Regulatory Affairs & Chief Safety Officer
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Andres A. Gutierrez M.D., PhD. Chief Medical Officer
Alan J. Tuchman M.D. Chief Neuro Oncology Research Officer
Age: 69
Angela Frances Holtham Director
Edwin Levy Ph.D. Director
J. Mark Lievonen Director